KIR2DL2 polyclonal Antibody | BS60168

KIR2DL2 polyclonal Antibody | BS60168 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: NKAT (NK-associated transcripts) gene products, known as killer immunoglobulin-like receptors or KIRs, downregulate the cytotoxicity of NK cells upon recognition of specific class I major histocompatibility complex (MHC) molecules on target cells. This family of receptors is characterized by an extracellular region with two to three immunoglobulin superfamily domains and a cytoplasmic domain with an antigen receptor activation motif (ARAM) . KIRs and other inhibitory receptors also possess a common cytoplasmic sequence (I/VxYxxL/V) known as an ITIM (immunoreceptor tyrosine-based inhibitory motif) . The human inhibitory natural killer cell immunoglobulin-like receptor 2DL1, also designated KIR2DL1, CL-42, NKAT1, P58.1 or CD158a long form, is a 348 amino acid type I transmembrane protein. KIR2DL1 can bind human leukocyte antigen-C (HLA-C) via both polar and hydrophobic interactions through Met 44 in a binding pocket that coordinates Lys 80 of HLA-C.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: KIR2DL2 polyclonal Antibody detects endogenous levels of KIR2DL2 protein.

Molecular Weight: ~ 34 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Killer cell immunoglobulin-like receptor 2DL2; CD158 antigen-like family member B1; MHC class I NK cell receptor; Natural killer-associated transcript 6; NKAT-6; p58 natural killer cell receptor clone CL-43; p58 NK receptor CL-43; CD158b1; CD158B1; NKAT6

Immunogen: A synthetic peptide corresponding to residues in Human KIR2DL2.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: